20 (Xinhua) -- Eli Lilly on Tuesday said preliminary data from a three-year study showed that its weight-loss drug significantly reduced the risk of progression to type 2 diabetes among adults with prediabetes and obesity or overweight. According to the pharmaceutical company, top-line data ...
For the next 20 years, they worked on that GLP-1 molecule before Ozempic finally made it to market as a type 2 diabetes drug; it took another four years for Wegovy to be approved for weight loss. It turned Novo Nordisk from niche player, to a company bigger than ...
is a new online resource designed to meet the evolving needs of physicians. It brings together elements from Advanstar's trusted healthcare journals along with powerful tools, resources, decision support and advisory functions.Mark LoweryContent EditorAdvanstar Communications Inc...
Amgen Raises Expectations for Weight-Loss Drug Discussinginterim datafrom a Phase 2 trial of the company’s weight-loss drug, Amgen CEO Robert Bradway said “we are very encouraged with results that we’ve seen thus far.” The firm did not release any of the results. Bradway added that...
for the company’s weight loss drugs and how they would stand apart in the wildly competitive field. Analysts asked what made the Roche drug candidates different, and how the company saw its lane given that it’s years behind other drugmakers, some of which already have products on the ...
When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years to lose weight, and it...
BEIJING, July 11 (TiPost) —— The first GLP-1 class weight loss drug called liraglutide produced by China has been approved for sale recently. The news put the producer Huadong Medicine in the spotlight and market observers started to examine the capital movements at the same time. ...
Eithther the 22.7% or the 20.4% of patients’ body weight loss, on average, fell short of the 25% weight loss that Novo Nordisk projected previously for its next-generation drug. The company has predicted CagriSema will help patients lose “at least 25%” of their body weight. That would...
Follow the latest Weight-loss drugs news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to Weight-loss drugs notifications.
Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults in two company trials, drug maker Eli Lilly announced Wednesday.